V
V. Chiarion-Sileni
Researcher at University of Sydney
Publications - 24
Citations - 591
V. Chiarion-Sileni is an academic researcher from University of Sydney. The author has contributed to research in topics: Ipilimumab & Nivolumab. The author has an hindex of 11, co-authored 22 publications receiving 546 citations.
Papers
More filters
Journal ArticleDOI
Correction to Lancet Oncol 2015; 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Journal ArticleDOI
Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Jeffrey S. Weber,M. Del Vecchio,Mario Mandalà,Helen Gogas,Ana Arance,Stéphane Dalle,Charles Lance Cowey,Michael Schenker,J.-J. Grob,V. Chiarion-Sileni,Ivan Marquez-Rodas,Marcus O. Butler,Michele Maio,Mark R. Middleton,T. Tang,Abdel Saci,V. de Pril,Maurice Lobo,J.M.G. Larkin,P.A. Ascierto +19 more
Journal ArticleDOI
Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031)
Wim H. J. Kruit,Stefan Suciu,B. Dréno,V. Chiarion-Sileni,Laurent Mortier,C. Robert,Michele Maio,Vincent Brichard,Frederic Lehmann,Ulrich Keilholz +9 more
TL;DR: The MAGE-A3 antigen, expressed in ±60% of metastatic melanomas, is a target of anti-tumor CD4+ and CD8+ T-cells and it is shown that this antigen acts as a ‘spatially aggregating force’ to drive T-cell reprograming in these patients.
Journal ArticleDOI
3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
C. Robert,Boguslawa Karaszewska,Jacob Schachter,Piotr Rutkowski,Andrzej Mackiewicz,Daniil Stroyakovskiy,Mikhail Lichinitser,R. Dummer,Florent Grange,Laurent Mortier,V. Chiarion-Sileni,Kamil Drucis,Ivana Krajsová,Axel Hauschild,Bijoyesh Mookerjee,Jeffrey J. Legos,Dirk Schadendorf +16 more
Journal ArticleDOI
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma
C. Robert,Boguslawa Karaszewska,Jacob Schachter,Piotr Rutkowski,Andrzej Mackiewicz,Daniil Stroyakovskiy,Reinhard Dummer,Florent Grange,Laurent Mortier,V. Chiarion-Sileni,Kamil Drucis,Ivana Krajsová,Axel Hauschild,Bijoyesh Mookerjee,Jeffrey J. Legos,Ying Zhang,Stephen R. Lane,Dirk Schadendorf +17 more